کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5857495 | 1132009 | 2013 | 10 صفحه PDF | دانلود رایگان |
An analysis of target organ toxicities in first time in man (FTiM) toxicity studies for 77 AstraZeneca candidate drugs (CDs) was conducted across a range of therapy areas. In the rodent, the most frequently affected organ was the liver followed by adrenal glands, kidney, spleen, bone marrow and thymus. In non-rodent, liver and thymus were the most frequently affected organs, followed closely by the testis and GI tract. The profile of affected organs was largely similar across the therapy areas of respiratory and inflammation, cardiovascular/gastrointestinal and CNS/pain. The oncology/infection therapy area differed with a larger range of organs affected. For the 75 CDs for which both rodent and non-rodent studies were conducted, new target organs were identified in non-rodents for 43 of the CDs. Notably, the changes seen only in non-rodents included organ systems of high relevance for human risk assessment such as the liver, male reproductive tissues and CNS. Additionally, profiles were similar for those CDs that progressed into human trials and those that did not. Overall, our data provide new insights into drug toxicity profiles in pre-clinical species and additionally confirm the value of using non-rodents as a second species in toxicity testing to support human safety.
⺠Target organ toxicities were analyzed in first time in man toxicity studies for 77 candidate drugs. ⺠The liver was the most common target organ noted across diverse therapy areas. ⺠Several changes of high significance for human risk assessment were seen only in non-rodents. ⺠These data confirm the value of non-rodents as a second species in toxicity testing. ⺠Overall, the analysis provides new insights into drug toxicity profiles in pre-clinical species.
Journal: Regulatory Toxicology and Pharmacology - Volume 65, Issue 3, April 2013, Pages 334-343